Published in AIDS Res Hum Retroviruses on October 10, 2012
Cell-associated transmission of HIV type 1 and other lentiviruses in small-animal models. J Infect Dis (2014) 0.82
Improving Adherence to Post-Cervical Biopsy Sexual Abstinence in Kenyan Female Sex Workers. Am J Reprod Immunol (2016) 0.75
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (2005) 4.71
Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS (2008) 4.21
In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One (2010) 4.08
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science (2004) 3.95
Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med (2008) 2.74
Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol (2009) 2.49
Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod (2005) 2.48
A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS (2008) 2.43
Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. J Infect Dis (2004) 2.29
Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Hum Reprod (2001) 2.26
HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep (2009) 2.18
Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med (2012) 2.06
High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr (2011) 1.74
In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide. BMC Infect Dis (2011) 1.56
Targeting Trojan Horse leukocytes for HIV prevention. AIDS (2010) 1.40
Animal models for microbicide studies. Curr HIV Res (2012) 1.17
Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol (2012) 1.15
Role of semen in HIV-1 transmission: inhibitor or facilitator? Am J Reprod Immunol (2010) 1.12
Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology (2012) 1.12
Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally. PLoS One (2011) 1.10
Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proc Natl Acad Sci U S A (2012) 1.03
Langerhans cells and viral immunity. Eur J Immunol (2008) 1.03
Short-chain fatty acids induce pro-inflammatory cytokine production alone and in combination with toll-like receptor ligands. Am J Reprod Immunol (2011) 1.01
Mobilization of HIV spread by diaphanous 2 dependent filopodia in infected dendritic cells. PLoS Pathog (2012) 1.01
Viruses and Langerhans cells. Immunol Cell Biol (2010) 0.91
Expression of structural proteins in human female and male genital epithelia and implications for sexually transmitted infections. Biol Reprod (2012) 0.91
Role of novel type I interferon epsilon in viral infection and mucosal immunity. Mucosal Immunol (2012) 0.90
Anti-HIV-1 antibody-dependent cellular cytotoxicity mediated by hyperimmune bovine colostrum IgG. Eur J Immunol (2012) 0.86
Overview. Type I interferons as primers, activators and inhibitors of innate and adaptive immune responses. Immunol Cell Biol (2012) 0.85
Finally, a macaque model for cell-associated SIV/HIV vaginal transmission. J Infect Dis (2010) 0.83
Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides. Antimicrob Agents Chemother (2012) 0.82
Innate and acquired immunity in the human penile urethra. J Reprod Immunol (2011) 0.82
Interferons as biomarkers and effectors: lessons learned from animal models. Biomark Med (2012) 0.81
Pigtailed macaque model refinement: topical microbicide safety in the presence of coitus. J Med Primatol (2011) 0.77
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med (2006) 8.41
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis (2009) 6.17
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol (2002) 3.66
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med (2007) 2.41
Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis (2010) 2.37
Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis (2006) 2.26
Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem (2008) 2.12
Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS (2002) 2.02
Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med (2002) 1.93
Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood (2012) 1.91
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Arch Intern Med (2007) 1.84
HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A (2003) 1.71
Interleukin-7-treated naive T cells can be productively infected by T-cell-adapted and primary isolates of human immunodeficiency virus 1. Blood (2002) 1.70
Treatment of intestinal worms is associated with decreased HIV plasma viral load. J Acquir Immune Defic Syndr (2002) 1.59
Early immune senescence in HIV disease. Curr HIV/AIDS Rep (2010) 1.58
The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages. Rev Med Virol (2003) 1.50
Anal sexually transmitted infections and risk of HIV infection in homosexual men. J Acquir Immune Defic Syndr (2010) 1.50
CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis (2008) 1.49
Reducing the burden of HIV/AIDS in infants: the contribution of improved diagnostics. Nature (2006) 1.48
Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis (2010) 1.42
Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levels. J Infect Dis (2007) 1.42
Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol (2007) 1.41
Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res (2008) 1.40
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses (2012) 1.35
Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine (2008) 1.33
HIV infection of dendritic cells subverts the IFN induction pathway via IRF-1 and inhibits type 1 IFN production. Blood (2011) 1.33
Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis (2006) 1.32
Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. J Infect Dis (2006) 1.31
CD4 immunophenotyping in HIV infection. Nat Rev Microbiol (2008) 1.27
Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. PLoS Pathog (2006) 1.25
Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer. J Virol (2005) 1.21
Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis (2004) 1.21
A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther (2007) 1.17
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis (2012) 1.17
Vaginal concentrations of lactic acid potently inactivate HIV. J Antimicrob Chemother (2013) 1.16
Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring. Curr HIV Res (2005) 1.15
Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. J Clin Invest (2014) 1.14
Reducing the burden of sexually transmitted infections in resource-limited settings: the role of improved diagnostics. Nature (2006) 1.13
Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS One (2010) 1.12
Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis (2003) 1.11
The relationship of T-regulatory cell subsets to disease stage, immune activation, and pathogen-specific immunity in HIV infection. J Acquir Immune Defic Syndr (2008) 1.10
GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. AIDS (2009) 1.09
Maturation of the HIV reverse transcription complex: putting the jigsaw together. Rev Med Virol (2009) 1.08
The packaging and maturation of the HIV-1 Pol proteins. Curr HIV Res (2005) 1.07
Marked structural and functional heterogeneity in CXCR4: separation of HIV-1 and SDF-1alpha responses. Immunol Cell Biol (2005) 1.06
A North American multilaboratory study of CD4 counts using flow cytometric panLeukogating (PLG): a NIAID-DAIDS Immunology Quality Assessment Program Study. Cytometry B Clin Cytom (2008) 1.06
Decoding the membrane activity of the cyclotide kalata B1: the importance of phosphatidylethanolamine phospholipids and lipid organization on hemolytic and anti-HIV activities. J Biol Chem (2011) 1.06
Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One (2012) 1.06
Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT. Biochem J (2007) 1.05
HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr (2003) 1.05
The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract. Curr HIV Res (2012) 1.05
Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS (2004) 1.03
SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS One (2011) 1.01
Mother-to-child transmission of HIV-1: strong association with certain maternal HLA-B alleles independent of viral load implicates innate immune mechanisms. J Acquir Immune Defic Syndr (2004) 1.01
MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr (2003) 1.01
CD1d-restricted natural killer T cells are potent targets for human immunodeficiency virus infection. Immunology (2003) 1.01
Regulatory B cell frequency correlates with markers of HIV disease progression and attenuates anti-HIV CD8⁺ T cell function in vitro. J Leukoc Biol (2013) 1.01
Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis (2005) 1.00
Discovery of retroviral homologs in bats: implications for the origin of mammalian gammaretroviruses. J Virol (2012) 1.00
Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1. Curr Med Chem (2005) 1.00
N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations. AIDS (2010) 0.99
CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies. J Infect Dis (2012) 0.98
Identification of diverse groups of endogenous gammaretroviruses in mega- and microbats. J Gen Virol (2012) 0.96
Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS (2007) 0.96
Identification of diverse full-length endogenous betaretroviruses in megabats and microbats. Retrovirology (2013) 0.96
The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs. J Virol (2009) 0.95
HIV type 1 and cytomegalovirus coinfection in the female genital tract. J Infect Dis (2004) 0.95
Immunophenotypic alterations in acute and early HIV infection. Clin Immunol (2007) 0.94
Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells. AIDS (2007) 0.94
Human cytomegalovirus and human immunodeficiency virus type-1 co-infection in human cervical tissue. Virology (2007) 0.93
Intracellular Casp8p41 content is inversely associated with CD4 T cell count. J Infect Dis (2010) 0.93
Chemokine analogues show suitable stability for development as microbicides. J Acquir Immune Defic Syndr (2008) 0.93
Phosphatidylethanolamine binding is a conserved feature of cyclotide-membrane interactions. J Biol Chem (2012) 0.92
GB virus C infection is associated with altered lymphocyte subset distribution and reduced T cell activation and proliferation in HIV-infected individuals. PLoS One (2012) 0.92
Increased glucose metabolic activity is associated with CD4+ T-cell activation and depletion during chronic HIV infection. AIDS (2014) 0.92
Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur J Biochem (2002) 0.91
Proinflammatory and type 1 cytokine expression in cervical mucosa during HIV-1 and human papillomavirus infection. J Acquir Immune Defic Syndr (2007) 0.91
Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1. Antiviral Res (2011) 0.91
Viruses and Langerhans cells. Immunol Cell Biol (2010) 0.91
Longitudinal assessment of pigtailed macaque lower genital tract microbiota by pyrosequencing reveals dissimilarity to the genital microbiota of healthy humans. AIDS Res Hum Retroviruses (2012) 0.91
Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability. Curr HIV Res (2008) 0.90
Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis (2003) 0.90
Analysis of the contribution of reverse transcriptase and integrase proteins to retroviral RNA dimer conformation. J Virol (2005) 0.89
Role of Baseline pol Genotype in HIV-1 Fitness Evolution. J Acquir Immune Defic Syndr (2003) 0.89
Dysfunctional natural killer cells, in vivo, are governed by HIV viremia regardless of whether the infected individual is on antiretroviral therapy. AIDS (2007) 0.89
A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. AIDS (2002) 0.88
Dynamics of cytokine expression in HIV productively infected primary CD4+ T cells. Blood (2004) 0.88
Marked differences in the structures and protein associations of lymphocyte and monocyte CD4: resolution of a novel CD4 isoform. Immunol Cell Biol (2006) 0.88
Interleukin-7 induces HIV replication in primary naive T cells through a nuclear factor of activated T cell (NFAT)-dependent pathway. Virology (2006) 0.87